Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.

Raffit Hassan; Elad Sharon; Anish Thomas; Jingli Zhang; Alexander Ling; Markku Miettinen; Robert J Kreitman; Seth M Steinberg; Kevin Hollevoet; Ira Pastan

首页> 外文期刊>Cancer: A Journal of the American Cancer Society >Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.

【24h】

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.

机译：相1研究抗血管前毒素的肺肺瘤和顺铂与胸腔间皮瘤前线治疗的相1研究及肿瘤反应与血清间皮素，巨核素增强因子和癌抗原125的相关性的相关性。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

SS1P given with pemetrexed and cisplatin is safe and well tolerated and exhibits significant antitumor activity in patients with unresectable, advanced pleural mesothelioma. Serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125 levels correlated with objective tumor responses.

机译：具有培养基和顺铂的SS1P是安全且耐受性良好的，并且在不可切除的晚期胸膜间皮瘤患者中表现出显着的抗肿瘤活性。血清间皮素，巨核细胞增强因子和癌症抗原125水平与物镜肿瘤反应相关。

著录项

来源
《Cancer: A Journal of the American Cancer Society》 |2014年第21期|共9页
作者
Raffit Hassan; Elad Sharon; Anish Thomas; Jingli Zhang; Alexander Ling; Markku Miettinen; Robert J Kreitman; Seth M Steinberg; Kevin Hollevoet; Ira Pastan;
展开▼
作者单位

Laboratory of Molecular Biology Center for Cancer Research National Cancer Institute National;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. [J] . Raffit Hassan, Elad Sharon, Anish Thomas, Cancer: A Journal of the American Cancer Society . 2014,第21期

机译：氨苄青霉素免疫毒素SS1P与培美曲塞和顺铂联合用于胸膜间皮瘤一线治疗以及肿瘤应答与血清间皮素，巨核细胞增强因子和癌症抗原125的一期研究。
2. Comparison of the diagnostic accuracy of the msln gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum [J] . CreaneyJ., SneddonS., DickI.M., Disease markers . 2013,第2期

机译：msln基因产物，间皮素和巨核细胞增强因子作为胸腔积液和血清中间皮瘤生物标志物的诊断准确性比较
3. Comparison of the Diagnostic Accuracy of theMSLNGene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum [J] . JenetteCreaney, SophieSneddon, Ian M.Dick, Disease markers . 2013,第2期

机译：作为胸膜积液和血清间皮瘤生物标志物的MSLNGene产品，间皮素和巨核细胞增强因子的诊断准确性的比较
4. Phase 1 Study of the Antimesothelin Immunotoxin SS1P in Combination With Pemetrexed and Cisplatin for Front-Line Therapy of Pleural Mesothelioma and Correlation of Tumor Response With Serum Mesothelin Megakaryocyte Potentiating Factor and Cancer Antigen 125 [O] . Raffit Hassan, Elad Sharon, Anish Thomas, -1

机译：氨苄青霉素免疫毒素SS1P联合培美曲塞和顺铂用于胸膜间皮瘤一线治疗以及血清间皮素巨核细胞增强因子和肿瘤抗原125与肿瘤反应的相关性的第一阶段研究
5. Comparison of the Diagnostic Accuracy of theMSLNGene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum [O] . Jenette Creaney, Sophie Sneddon, Ian M. Dick, 2013

机译：胸腔内产物，间皮素和巨核细胞增强因子的诊断准确性的比较，作为胸腔生效和血清中型中瘤的生物标志物

Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.

摘要

著录项

相似文献

相关主题

期刊订阅